- Trials with a EudraCT protocol (239)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (19)
239 result(s) found for: Onset of action.
Displaying page 1 of 12.
EudraCT Number: 2011-004725-27 | Sponsor Protocol Number: GA1109 | Start Date*: 2012-01-24 |
Sponsor Name:Reckitt Benckiser Healthcare (UK) Ltd | ||
Full Title: A single-centre, randomised, double-blind, two-way crossover, placebo-controlled pilot study, investigating the use of a novel intragastric and oesophageal pH catheter to characterise the antacid a... | ||
Medical condition: To pilot the use of a novel pH catheter for the measurement of oesophageal and intragastric pH comparing the onset and duration of antacid action of Gaviscon Double Action versus placebo. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-000539-42 | Sponsor Protocol Number: RB2-NL-1518 | Start Date*: 2016-04-15 |
Sponsor Name:Reckitt Benckiser Healthcare (UK) Limited | ||
Full Title: A randomised, single dose, crossover, open label, placebo controlled confirmatory study in healthy volunteers to characterise the acid neutralisation activity of Gaviscon Double Action Liquid in th... | ||
Medical condition: To investigate the pH of the acid in the stomach of healthy volunteers after the intakeof Gaviscon Double Action liquid. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-006413-25 | Sponsor Protocol Number: GA0821 | Start Date*: 2008-12-09 |
Sponsor Name:Reckitt Benckiser Healthcare (UK) Limited | ||
Full Title: A single-centre randomised, partially blind, single dose, crossover study investigating the onset of action of soothing and cooling after taking Gaviscon Peppermint liquid, Double Action Gaviscon ... | ||
Medical condition: Symptoms of heartburn | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-005821-31 | Sponsor Protocol Number: GA0706 | Start Date*: 2008-01-15 |
Sponsor Name:Reckitt Benckiser Healthcare UK) Limited [...] | ||
Full Title: A single-centre randomised, partially blind, single dose, crossover pilot study investigating the use of stopwatches to assess the onset of action of soothing and cooling of Gaviscon Peppermint Liq... | ||
Medical condition: Symptoms of heartburn | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-003158-15 | Sponsor Protocol Number: GA1406 | Start Date*: 2014-10-10 |
Sponsor Name:Reckitt Benckiser Healthcare (UK) Limited | ||
Full Title: A randomised, assessor blind, placebo controlled exploratory study in healthy volunteers, to characterise the acid neutralisation activity of sodium alginate oral suspension in the fasted state, us... | ||
Medical condition: To pilot the use of a custom designed pH catheter for the measurement of intragastric pH to characterise the antacid action of Gaviscon Double Action versus placebo. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-012201-19 | Sponsor Protocol Number: EX2211-3748 | Start Date*: 2010-08-24 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: LEADER Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results A Long-term, Multi-centre, International, Randomised Double-blind, Placebo-controlled Trial to Determi... | |||||||||||||
Medical condition: Type 2 diabetes mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) IE (Completed) SE (Completed) DE (Completed) NL (Completed) FI (Completed) AT (Completed) GB (Completed) CZ (Completed) BE (Completed) DK (Completed) PL (Completed) GR (Completed) ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004343-76 | Sponsor Protocol Number: NMBA_ELDERLY2019ROCU_DOSES | Start Date*: 2020-02-27 | |||||||||||
Sponsor Name:Rigshospitalet | |||||||||||||
Full Title: A single-blinded multicenter randomized interventional study of rocuronium 0.3 mg/kg, and 0.9 mg/kg comparing onset time, duration of action and effect on intubating conditions in elderly patients ... | |||||||||||||
Medical condition: The aim of this study is to determine the onset time, duration of action and effect on intubating conditions after rocuronium 0.3 mg/kg and 0.9 mg/kg in patients with age ≥ 80 years. | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-002807-33 | Sponsor Protocol Number: NLA-C003P | Start Date*: 2004-11-09 |
Sponsor Name:Biolipox AB | ||
Full Title: A double blind, randomized, cross-over, placebo controlled study, evaluating the time-to-onset of action of BLX000441-002 nasal spray in healthy volunteers. | ||
Medical condition: healthy volunteers | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2005-005702-23 | Sponsor Protocol Number: BY217/M2-401 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Nycomed GmbH | |||||||||||||
Full Title: Efficacy of 500µg roflumilast once daily versus placebo over 12 weeks in patients with diabetes mellitus type 2. A double blind, parallel group, phase IIb, proof of concept clinical study | |||||||||||||
Medical condition: Diabetes mellitus type 2 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-001771-11 | Sponsor Protocol Number: 0431-061 | Start Date*: 2007-07-02 | |||||||||||
Sponsor Name:MERCK SHARP DOHME | |||||||||||||
Full Title: A Phase I Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Study the Safety, Efficacy, and Mechanism of Action of Sitagliptin and Pioglitazone in Patients With Type 2 Diabetes Mell... | |||||||||||||
Medical condition: Type 2 diabetes mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-008296-33 | Sponsor Protocol Number: 1218.36 | Start Date*: 2009-06-29 | ||||||||||||||||||||||||||
Sponsor Name:Boehringer Ingelheim Finland Ky | ||||||||||||||||||||||||||||
Full Title: A Phase III randomised, double-blind, placebo-controlled, parallel group efficacy and safety study of Linagliptin (5 mg), administered orally once daily for at least 52 weeks in type 2 diabetic pa... | ||||||||||||||||||||||||||||
Medical condition: Type 2 diabetes pretreated with basal Insulin therapy | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: FI (Completed) DE (Completed) NL (Completed) ES (Completed) SK (Completed) BE (Completed) CZ (Completed) IT (Completed) SE (Completed) GR (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-000780-27 | Sponsor Protocol Number: SPRINK-01 | Start Date*: 2011-04-19 | |||||||||||
Sponsor Name:Medizinische Universität Graz | |||||||||||||
Full Title: A single-center, randomized, controlled, 2-period cross-over, open-labelled trial to evaluate the impact of different application volumes on pharmacokinetic and pharmacodynamic properties of insul... | |||||||||||||
Medical condition: Diabetes mellitus type I | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003202-27 | Sponsor Protocol Number: FAST-TOT401-19 | Start Date*: 2020-05-20 | |||||||||||
Sponsor Name:Laboratoire Innotech Internationnal | |||||||||||||
Full Title: Assessment of the eFficacy, the onset-of-Action and the Safety of Tot'héma ® in adults with moderate iron deficiency anaemia | |||||||||||||
Medical condition: Moderate iron deficiency anaemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) BG (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-007146-34 | Sponsor Protocol Number: 2008-3-1 | Start Date*: 2008-09-02 | |||||||||||
Sponsor Name:Steno Diabetes Center | |||||||||||||
Full Title: The Anti-Interleukin-1 in Diabetes Action trial | |||||||||||||
Medical condition: new-onset Type 1 diabetes | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) DE (Completed) ES (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-004918-22 | Sponsor Protocol Number: AGO/2015/011 | Start Date*: 2016-06-28 |
Sponsor Name:Ghent University Hospital | ||
Full Title: A comparison of chloroprocaine 3% versus levobupivacaine 0.5% for epidural anesthesia during caesarean section. | ||
Medical condition: anesthetics for women scheduled for elective caesarean section | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-002854-25 | Sponsor Protocol Number: CYD65 | Start Date*: 2020-09-13 |
Sponsor Name:Sanofi Pasteur SA | ||
Full Title: Immunogenicity and Safety of Tetravalent Dengue Vaccine Given in 1-, 2-, or 3-Dose Schedules (STAGE I) Followed by a Single Booster Injection of the Same Vaccine (STAGE II) 1 or 2 Years after the L... | ||
Medical condition: Dengue Fever Dengue Hemorrhagic Fever | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2013-003042-16 | Sponsor Protocol Number: Samba-02 | Start Date*: 2013-09-24 | |||||||||||
Sponsor Name:Dance Biopharm, Inc. | |||||||||||||
Full Title: Samba-02: An Investigation of the Dose-Response and Subject Variability of Inhaled Insulin in Subjects with Type 2 Diabetes | |||||||||||||
Medical condition: Diabetes mellitus type 2 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-000473-22 | Sponsor Protocol Number: CLAF237A2384 | Start Date*: 2005-10-11 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A multicenter, randomized, double-blind study to compare the effects of 24 weeks treatment with LAF237 (50 mg qd, 50 mg bid or 100 mg qd) to placebo in drug naïve patients with type 2 diabetes | |||||||||||||
Medical condition: Type II Diabetes | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-005101-64 | Sponsor Protocol Number: 059 | Start Date*: 2007-11-28 | |||||||||||
Sponsor Name:MERCK SHARP DOHME | |||||||||||||
Full Title: A Randomized, Placebo-Controlled Study to Evaluate the Safety, Efficacy and Mechanism of Action of MK-0431/Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control | |||||||||||||
Medical condition: type 2 diabetes | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-002027-16 | Sponsor Protocol Number: RPCG06B2433 | Start Date*: 2006-12-12 |
Sponsor Name:UCB AE | ||
Full Title: Certolizumab pegol 400 mg monthly in the treatment of adult Greek patients with moderate to severe Crohn’s Disease, who have been previously treated successfully with infliximab but who have subseq... | ||
Medical condition: Certolizumab pegol in the treatment of adult Greek patients with moderate to severe Crohn’s Disease, who have been previously treated successfully with infliximab but who have subsequently lost the... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GR (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
